文献速递MDS 与骨髓增殖性肿瘤造血干细胞移植与细胞治疗

移植前减瘤与移植后维持对MDS异基因移植结局的相反影响:真实世界多中心证据

Contrasting impacts of pretransplant cytoreduction and post-transplant maintenance on outcomes of allogeneic haematopoietic stem cell transplantation in myelodysplastic syndromes: Real-world multicentre evidence.
PubMed 文献 · Br J Haematol · 2026-04-10

该回顾性多中心研究分析215例接受异基因造血干细胞移植的高危MDS患者,评估临床、分子及移植相关因素对复发、无复发生存和总生存的影响。结果显示移植前减瘤未带来可测量获益,而移植后维持治疗显著降低复发并延长无复发生存,供者年龄和CD34+细胞剂量是可干预的移植变量。

要点

  • 移植前减瘤未改善MDS患者 allo-HSCT 结局。
  • 移植后维持治疗显著降低复发并延长无复发生存。
  • 年轻供者(<42岁)和高CD34+剂量(≥3.1×10^6/kg)降低复发风险。

核心结论

  • 移植前减瘤临床价值有限,而移植后维持治疗和可干预移植变量(CD34+细胞剂量与供者年龄)可显著改善MDS患者allo-HSCT结局。

研究设计与样本

  • 回顾性多中心分析215例连续接受allo-HSCT的MDS患者,评估临床、分子及移植相关因素对复发、RFS和OS的影响。

主要发现

  • TP53突变、复杂核型和减瘤治疗后MRD阳性与复发风险增加相关。
  • 供者年龄<42岁和CD34+细胞剂量≥3.1×10^6/kg显著降低复发风险。
  • 移植前减瘤未显示可测量的结局获益。
  • 移植后维持治疗显著降低复发发生率并延长RFS。

关键数值与推荐

  • 供者年龄<42岁与CD34+细胞剂量≥3.1×10^6/kg为与复发风险降低相关的移植变量。
  • TP53突变、复杂核型及减瘤后MRD阳性为复发风险增加相关因素。

临床怎么用

  • MDS患者allo-HSCT决策中应重视移植后维持治疗及优化供者选择和CD34+细胞剂量,而非依赖移植前减瘤。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Allogeneic haematopoietic stem cell transplantation (allo-HSCT) remains the only curative therapy for patients with high-risk myelodysplastic syndrome (MDS). However, the optimal timing and value of pretransplant cytoreduction and post-transplant maintenance remain unclear, and transplant-modifiable variables are not well defined in real-world settings. We retrospectively analysed 215 consecutive MDS patients who underwent allo-HSCT. Clinical, molecular and transplant-related factors were evaluated for their impact on relapse, relapse-free survival (RFS) and overall survival (OS). TP53 mutation, complex karyotype, and positive measurable residual disease (MRD) after cytoreductive treatment were associated with increased relapse risk. Among transplant-related variables, younger donor age (<42 years) and higher CD34+ cell dose (≥3.1 × 106/kg) significantly reduced relapse risk. Notably, pretransplant cytoreduction did not confer measurable benefit on outcomes. In contrast, post-transplant maintenance therapy significantly reduced relapse incidence and prolonged RFS. Pretransplant cytoreduction offers limited clinical value, whereas post-transplant maintenance and modifiable transplant variables (CD34+ cell dose and donor age) substantially improve outcomes after allo-HSCT for MDS. These findings highlight actionable strategies that may refine transplant decision-making and optimize outcomes in clinical practice.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Chen Y, Zhang X, Shen N, et al. Contrasting impacts of pretransplant cytoreduction and post-transplant maintenance on outcomes of allogeneic haematopoietic stem cell transplantation in myelodysplastic syndromes: Real-world multicentre evidence. Br J Haematol. 2026. PMID: 41960892. doi:10.1111/bjh.70477

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。